Table 44 (Abstract P159). See text for description
From: Proceedings of the 24th Paediatric Rheumatology European Society Congress: Part one
Results table | |||||||
|---|---|---|---|---|---|---|---|
bDMARD | No. patients | No. treatment years | Observed no. infections | Infections per 100 patient years | Observed no. adverse events | Adverse events per 100 patient years | % changed for ongoing JIA or uveitis |
1st agent | 34 | 51.1 | 64 | 3.68 | 23 | 3.68 | 58.8% |
2nd agent | 34 | 77.8 | 76 | 2.87 | 12 | 0.45 | 70% |
3rd agent | 10 | 5.8 | 10 | 17.39 | 2 | 3.48 | 25% |
4th agent | 4 | 5.3 | 8 | 37.5 | 0 | 0 | - |
Total | Â | 1680 | 158 | Â | Â | Â | Â |